Asymchem to Operate Development and Manufacturing Facilities at Former Pfizer API Pilot Plant in Sandwich (UK)
Wednesday, May 22, 2024
Asymchem Laboratories (Tianjin) Co, Ltd. (stock codes: 002821.SZ/6821.HK) today announced that it will operate Pfizer UK's former small molecule API pilot plant, as well as part of its development laboratories, in as part of a new lease agreement between Asymchem and Discovery Park, establishing Asymchem's first manufacturing footprint in Europe. Asymchem will continue to operate the Sandwich, Kent site as a clinical small molecule development and manufacturing facility to meet international customers' demands for pharmaceutical services and supplies.
The development laboratories are expected to start operating in June 2024, followed by the API pilot plant which will begin operations in August. The site is expected to employ around 100 staff by the end of 2024, including many people previously employed by Pfizer. Additions are planned at the site, including peptide and oligonucleotide manufacturing capabilities, as well as sustainability capabilities using continuous flow and biocatalysis.
“ We are delighted to now be part of the European pharmaceutical manufacturing community,” said Dr. Hao Hong, CEO of Asymchem Group. “ Meeting the needs of our customers and global business demands by launching manufacturing operations in the Western market will continue to be part of our long-term strategy. »
Mayer Schreiber, CEO of Discovery Park, said: “ We are very pleased to welcome Asymchem to Discovery Park this summer. The company has chosen the park as its European base and location for its first manufacturing plant in Europe, which will allow it to create new jobs and preserve scientific talent. Asymchem joins a growing community of more than 160 companies in an area designated as the Life Sciences Opportunity Zone, representing an incredible talent pool that contributes significantly to the life sciences economic sector. life in the UK. »
About Asymchem
Asymchem is a technology-driven, global contract development and manufacturing organization (CDMO) serving the pharmaceutical industry. Founded in 1997, Asymchem employs more than 9,300 people worldwide, with its research and development and manufacturing operations based in China and the United States.
Forward-looking statements
This press release may contain forward-looking statements which are, by their nature, subject to significant risks and uncertainties. Words such as "anticipate", "believe", "estimate", "expect", "intend" and other similar expressions, as they relate to the Company, are intended to identify certain of these forward-looking statements. The Company does not expect to regularly update these forward-looking statements. These forward-looking statements are based on the beliefs, assumptions, expectations, estimates, projections and knowledge of the Company's management regarding future events at the time such statements are made. These statements are not guarantees of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the control of the Company and are difficult to predict. Therefore, actual results could differ materially from the information contained in the forward-looking statements due to a number of factors, including, but not limited to, future changes or developments in our business, the competitive environment in which the Society evolves, as well as the political, economic, legal and social conditions.
The Company, its directors and employees undertake (a) no obligation to correct or update any forward-looking statements contained in this release; and (b) no liability if any forward-looking statements fail to materialize or prove to be incorrect.
About Discovery Park
Discovery Park is a thriving UK-based life sciences community catering to visionary entrepreneurs and leaders. Situated close to London, Discovery Park is the spearhead of Kent's thriving science and technology hub.
Discovery Park offers state-of-the-art laboratories, modern offices and manufacturing facilities, unrivaled flexibility and comprehensive support, including access to financing and a strong local talent pipeline.
Discovery Park has been a major life sciences center for nearly 70 years that hosts a growing community of more than 160 corporate tenants, ranging from dynamic startups to global corporations. The park is home to Algaecytes, Canterbury Christ Church University, Concept Life Sciences, eXroid, Genea Biomedx, LGC, Pfizer, Psyros Diagnostics, Salvensis, Viatris, VisusNano and Wren Healthcare, among others.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation must always be compared with the source text, which will set a precedent.
Contacts
Jake Knorr
Senior Director of Marketing
jakeknorr@asymchem.com
Source: businesswire.com
